1. Introduction {#s0005}
===============

Autism spectrum disorder (ASD) is one of the most serious neurodevelopmental conditions worldwide, affecting on average 1 in 150 children ([@bb0235]). The hallmarks of ASD include impaired social communication skills and repetitive behaviors, frequently co-occurring with intellectual disability ([@bb0015]). There are limited treatment options for ASD symptoms, and thus there is a great need to develop strategies that would improve the quality of life in ASD subjects. More recently, the gut microbiome has emerged as a novel important player and therapeutic target in autism ([@bb0365]). Intestinal bacteria can orchestrate a range of gastrointestinal (GI) functions ([@bb0340]), and therefore are poised to affect gut-brain axis signaling in ASD. Animal studies have demonstrated that the gut microbiota plays a crucial role in anxiety ([@bb0275]), cognitive performance ([@bb0075]), repetitive behaviors ([@bb0070]) and social communications ([@bb0040]; [@bb0325]). There is a growing body of evidence that ASD subjects display substantial alterations in microbiota composition, along with marked symptoms of GI distress, including changes to bowel habits, increased intestinal permeability, bloating and abdominal pain ([@bb0010]; [@bb0080]; [@bb0165]; [@bb0230]; [@bb0245]; [@bb0350]). In a recent small open-label clinical study, transplantation of standardized human gut microbiota to ASD-diagnosed children induced an improvement of GI function, as well as a reduction of behavioral ASD scoring ([@bb0170]). However, we do not yet know whether alterations in the gut microbiota in autism can in itself affect either behavioral or GI symptoms of ASD.

Identification of specific bacterial taxa and associated bacterial metabolites that can trigger changes in GI physiology and modulate the onset of autistic behaviors is thus an important quest in the search for precision microbiota-based therapeutics in ASD ([@bb0115]). Preclinical research is crucial in this endeavor ([@bb0140]; [@bb0210]). The BTBR *T*^*+*^ *Itpr3*^*tf*^/J mouse strain is one of the most widely used models of ASD. Similar to humans, these animals display robust deficits in social interactions and enhanced engagement in repetitive behaviors ([@bb0255]; [@bb0260]). Moreover, the autistic-like behavior of BTBR mice is largely driven by multiple genetic alterations ([@bb0250]), but is also sensitive to environmental influences, such as dietary intervention ([@bb0305]). Changes to a few bacterial taxa have also been recently reported in the BTBR intestine ([@bb0055]; [@bb0200]; [@bb0280]). Together, these findings strengthen the utility of the BTBR strain in understanding dysfunctional microbiota-gut-brain signaling in ASD. To this end, we characterized GI physiology in BTBR mice and found substantial abnormalities in both intestinal barrier function and intestinal transit. We identified changes in bile acid and tryptophan metabolism as putative mechanisms underlying GI dysfunction in these animals. We further associated the observed changes in GI physiology with a reduction in the abundance of certain bacterial taxa in the BTBR microbiota.

2. Materials and Methods {#s0010}
========================

2.1. Animals {#s0015}
------------

C57BL/6 J (Harlan, UK) and BTBR *T*^*+*^ *Itpr3*^*tf*^/J (The Jackson Laboratory, US) adult male mice were group housed under a 12 h light-dark cycle; standard rodent chow and water were available *ad libitum*. All experiments were performed in accordance with European guidelines following approval by University College Cork Animal Ethics Experimentation Committee.

2.2. Study Design {#s0020}
-----------------

Three independent cohorts participated in the study (Fig. S1). Detailed information on procedures with references is provided in Supplemental Methods.

2.3. Behavioral Assessment {#s0025}
--------------------------

Social behavior was analyzed in the three-chamber, social transmission of food preference and resident-intruder tests; compulsive behavior in the marble burying and self-grooming tests; anxiety-like behavior in the open field and elevated plus maze tests; depressive-like behavior in the forced swim test; cognitive performance in the novel object recognition test.

2.4. Plasma Corticosterone in Response to an Acute Stressor {#s0030}
-----------------------------------------------------------

Corticosterone levels were measured in plasma prior to (baseline) and after the onset of the forced swim test.

2.5. Fecal Water Content {#s0035}
------------------------

Water content in feces was calculated as the difference in weight after desiccation of fecal pellets.

2.6. Whole Intestinal Transit {#s0040}
-----------------------------

A test mouse was administered with carmine dye by oral gavage; the latency for the excretion of the first red-colored fecal pellet was recorded.

2.7. Colonic Transit {#s0045}
--------------------

An artificial pellet was inserted into the proximal end of the isolated colon, and the spontaneous propagation of the pellet in anterograde direction was video recorded. The latency to initiate the propagation and the velocity of propagation were scored.

2.8. Intestinal Permeability {#s0050}
----------------------------

Intestinal tissue samples were mounted into the Ussing chambers. Short-circuit current (*I*~*sc*~) was recorded in a zero voltage clamp mode; transepithelial electrical resistance (TEER) was measured by discharging a 2 mV pulse. 4 kDa FITC-dextran was added to the mucosal chamber at a final concentration of 2.5 mg/mL; 200 μL samples were collected from the serosal chamber every 30 min for the following 3 h.

2.9. Myenteric Plexus Morphology {#s0055}
--------------------------------

Myenteric plexus (MP) of distal colon was subjected to immunoflourescent staining against choline acetyltransferase (ChAT), HuC/HuD and nNOS. To analyze the morphology of MP, the following parameters were calculated in anti-ChAT stained tissues: the area occupied by MP; the mean thickness and the contact ratio of MP; the mean Feret diameter of interganglionic space. The numbers of HuC/HuD- and nNOS-positive myenteric neurons were quantified per visual field.

2.10. Tryptophan, Kynurenine and Serotonin Levels {#s0060}
-------------------------------------------------

Serotonin was measured in intestinal tissue samples by HPLC coupled to electrochemical detection. Kynurenine and tryptophan concentrations were determined in plasma by HPLC coupled to ultraviolet (230 nm) and fluorescent (254 nm excitation and 404 nm emission wavelengths) detection, accordingly.

2.11. Gene Expression Analysis {#s0065}
------------------------------

Total RNA was extracted from the intestinal tissue and the front lobe of the liver with the Qiagen RNeasy Plus Universal Mini kit, and from the right hippocampus with the Ambion *mir*Vana™ miRNA Isolation Kit. Genes of interest were amplified with real-time RT-PCR using TaqMan probes (Table S1). Data were analyzed with the comparative cycle threshold method (2^−ΔΔCt^) and presented as a fold change vs. C57BL/6 group.

2.12. Bile Acid Levels in Plasma and Fecal Material {#s0070}
---------------------------------------------------

Fecal and plasma bile acids and salts were extracted following addition of deuterated internal standards (IS). Extracted acids were resuspended in 50% methanol, injected in triplicate and assessed in negative electrospray mode through a C18 Acquity column using a LCT Premier mass spectrometer (Waters Corp). Assessment of extraction efficiency was performed using IS, and samples were quantified by standard curve construction for individual bile moieties using targetlynx software (Waters).

2.13. Microbiota Composition and Short Chain Fatty Acids Analysis in the Cecal Content {#s0075}
--------------------------------------------------------------------------------------

DNA was extracted using the Qiagen QIAmp Fast DNA Stool Mini Kit coupled with an initial bead-beating step. The V3-V4 hypervariable region of the 16S rRNA gene was amplified and prepared for sequencing as outlined in the Illumina 16S Metagenomic Sequencing Library Protocol. Samples were sequenced at Clinical-Microbiomics (Copenhagen, Denmark) on the Illumina MiSeq platform using a 2 × 300 bp kit. Reads were assembled, processed and analyzed following the pipeline, described in Supplemental Methods. Short chain fatty acids (SCFAs) were measured by gas chromatography, using a Varian 3500 GC flame-ionization system fitted with a ZB-FFAP column.

2.14. Statistical Analysis {#s0080}
--------------------------

Normally distributed data are presented as mean ± SEM; unpaired two-tailed *t*-test and mixed-design ANOVA were applied to analyze the differences between groups. Non-parametric datasets, as well as discrete data, are presented as median (IQR). Mann-Whitney test was used for between-group comparisons. Spearman\'s rank correlation coefficient was employed for the correlation analysis in the pooled datasets. A *p* value \< 0.05 was deemed significant in all cases.

3. Results {#s0085}
==========

3.1. BTBR Mice Display Marked Changes in the Intestinal Microbiota {#s0090}
------------------------------------------------------------------

The 16S sequencing revealed a substantial reduction in the bacterial species diversity in the BTBR cecum ([Fig. 1](#f0005){ref-type="fig"}a). Principal coordinate analysis showed a clear separation of BTBR and C57BL/6 microbiotas ([Fig. 1](#f0005){ref-type="fig"}b). We detected 9 phyla, 23 families and 41 bacterial genera in C57BL/6 and BTBR mice (Table S2). At the phylum level, BTBR mice displayed a distinct shift towards an increase in *Bacteroidetes* and a decrease in *Firmicutes*; these are two major bacterial phyla altogether comprising \> 90% of murine intestinal microbiota ([Fig. 1](#f0005){ref-type="fig"}c). The bloom in *Bacteroidetes* was mainly driven by an increase in *S24--7 uncultured bacterium,* a dominant genus of *S24--7* family. Interestingly, this seems to have happened at the expense of minor *Bacteroidetes* genera such as *Odoribacter*, *Parabacteroides*, *RC9 gut group* and *Rikenella*, which all showed a reduction in relative abundance. A decrease in *Firmicutes* was largely driven by *Lachnospiraceae* family, in particular *Blautia* bacteria, but also *Lachnospiraceae_Incertae Sedis* and *Coprococcus*. BTBR mice also displayed an increase in *Akkermansia*, *Bacteroides* and *Bilophila* genera, as well as a reduction in *Bifidobacterium* and *Desulfovibrio* (Table S2). With such a prominent shift in the microbiota composition, it was perhaps not surprising that BTBR mice also displayed significant changes in the SCFAs levels in the gut lumen ([Fig. 1](#f0005){ref-type="fig"}d). Overall, BTBR mice seem to have a very robust phenotype of the gut microbiota. For example, a similar increase in *Akkermansia* and a reduction in *Bifidobacterium* numbers in the BTBR cecum were shown in previous reports ([@bb0200]; [@bb0280]). In the fecal material of BTBR mice, Coretti et al. found a different pattern of changes in the microbiota composition ([@bb0055]); however, care should be taken when comparing cecal and fecal bacterial communities.Fig. 1Altered microbiota composition and short chain fatty acid levels in BTBR mice (a--b) BTBR cecal microbiota showed lower diversity of bacterial species, and was clearly separated from the microbiota of C57BL/6 mice. (c) Heatmap of log2 fold change ratio showing increases (red) or decreases (blue) in most abundant bacteria in BTBR compared to C57BL/6 mice. Significant changes are bolded (for details, see Table S2). (d) Short chain fatty acid cecal levels were differentially changed in BTBR mice. \**p* \< 0.05 for BTBR vs. C57BL/6 group. *Statistical analysis*: data are presented as median with IQR and min/max values as error bars on (a), and as mean + SEM on (d). *N* = 9 for C57BL/6 and *N* = 10 for BTBR group. *U*~(17)~ = 0.000, *p* \< 0.0005 for Chao1 index; *U*~(17)~ = 15.5, *p* = 0.013 for Simpson index; *U*~(17)~ = 0.000, *p* \< 0.0005 for Shannon index; *U*~(17)~ = 0.000, *p* \< 0.0005 for No of species, Mann-Whitney test. *t*~(17)~ = 2.424, *p* = 0.027 for acetate; *t*~(17)~ = − 0.265, *p* = 0.794 for propionate; *t*~(17)~ = − 2.887, *p* = 0.010 for n-butyrate; *t*~(17)~ = 4.023, *p* = 0.001 for i-butyrate, unpaired *t*-test.Fig. 1

3.2. BTBR Mice Show Delayed Intestinal Transit {#s0095}
----------------------------------------------

Among GI comorbidities associated with ASD, changes in bowel habits, in particular constipation, are the most prevalent ([@bb0245]). Hence, we examined intestinal motility, and found that whole intestinal transit was significantly delayed in BTBR mice ([Fig. 2](#f0010){ref-type="fig"}a). Further, BTBR mice displayed an elongated colon and decreased fecal water contents ([Fig. 2](#f0010){ref-type="fig"}b--c), both observations suggesting that the propagation of fecal matter along the colon was substantially slowed. The follow-up *ex vivo* analysis of colonic motility provided clear evidence of impaired transit in the BTBR large intestine. Indeed, it took almost twice as long to initiate spontaneous propagation of the pellet along the colon, and there was a trend towards a reduction in the velocity of oral-to-anal propulsion in BTBR mice ([Fig. 2](#f0010){ref-type="fig"}d). Measuring small intestinal transit in BTBR mice would be of interest for the future studies, particularly bearing in mind that impaired small intestinal motility was previously reported in a rat model of ASD ([@bb0195]).Fig. 2Delayed intestinal transit and impaired serotonin metabolism in BTBR mice: implication of microbiota (a--c) BTBR mice showed delayed whole intestinal transit, as well as an elongated colon and decreased fecal water contents. (d) Colonic transit was impaired in BTBR mice. (e--f) Serotonin (5-HT) tissue levels were reduced in both small and large intestine of BTBR mice. This was coupled with alterations in the expression of genes involved in tryptophan metabolism. (g) Intestinal transit rate and 5-HT levels were strongly associated with the relative abundance of *Blautia* bacteria (see also Table S3). \**p* \< 0.05 for BTBR vs. C57BL/6 group. *Statistical analysis*: data are presented as mean + SEM; *n* = 8 for C57BL/6 and *n* = 6 for BTBR group for (d), *n* = 9--10 in either group for the rest. *t*~(18)~ = − 4.524, *p* \< 0.0005 for the intestinal transit time; *t*~(18)~ = − 14.053, *p* \< 0.0005 for the colon length; *t*~(12)~ = − 4.107, *p* = 0.001 for the latency to initiate propagation; *t*~(11)~ = 1.599, *p* = 0.138 for the propulsive activity; *t*~(17)~ = 3.597, *p* = 0.002 for 5-HT levels and *t*~(15)~ = − 1.814, *p* = 0.09 for 5-HT/5-HIAA ratio in the colon; *t*~(17)~ = 5.069, *p* \< 0.0005 for *Tph1*, *t*~(18)~ = 1.928, *p* = 0.070 for *P11*, *t*~(16)~ = 4.578, *p* = 0.003 for *Ido1*, *t*~(18)~ = 3.835, *p* = 0.006 for *Tdo2* and *t*~(18)~ = − 4.851, *p* \< 0.0005 for *Sert* gene expression in the colon; *t*~(17)~ = 4.164, *p* = 0.001 for 5-HT levels and *t*~(8)~ = − 0.930, *p* = 0.380 for 5-HT/5-HIAA ratio in the ileum; *t*~(17)~ = 2.311, *p* = 0.034 for *Tph1*, *t*~(17)~ = 2.533, *p* = 0.021 for *P11*, *t*~(16)~ = 9.546, *p* \< 0.0005 for *Ido1*, *t*~(18)~ = − 14.655, *p* \< 0.0005 for *Sert* and *t*~(18)~ = − 2.739, *p* = 0.013 for *Tdo2* gene expression in the ileum, unpaired *t*-test. Spearman\'s rho was employed for the correlation analysis in the pooled datasets.Fig. 2

3.3. Impaired Serotonin Production in the BTBR Intestine {#s0100}
--------------------------------------------------------

The release of mucosal serotonin (5-HT) triggers intestinal peristalsis ([@bb0135]). To address the potential contribution of 5-HT metabolism to the delayed transit in the BTBR intestine, we assessed 5-HT availability in colonic and ileal tissue samples. We observed a 50% reduction in 5-HT tissue levels in both small and large intestine of BTBR mice, which was coupled with a down-regulation of *Tph1* and an up-regulation of *Sert* gene expression ([Fig. 2](#f0010){ref-type="fig"}e--f). Tph activity determines the amount of 5-HT which is produced from dietary tryptophan and released from enterochromaffin cells, while Sert controls the rate of 5-HT re-uptake and consequent breakdown in enterocytes ([@bb0240]). In line with the gene expression data, the ratio between 5-HIAA (the major metabolite of 5-HT) and 5-HT tended to be increased in the BTBR intestine ([Fig. 2](#f0010){ref-type="fig"}e--f). Together, these findings suggest reduced bioavailability of 5-HT in the BTBR gut due to a decrease in 5-HT synthesis and an increase in 5-HT breakdown. Alternatively to 5-HT, dietary tryptophan in the intestine can be metabolized along the kynurenine route. Ido1 and Tdo2 are two rate-limiting enzymes in this metabolic pathway. We found that the expression levels of both *Ido1* and *Tdo2* genes were markedly down-regulated in the BTBR colon. Interestingly, opposite changes in *Ido1* and *Tod2* genes were observed in the small intestine of BTBR mice ([Fig. 2](#f0010){ref-type="fig"}e--f).

3.4. Intestinal Transit and Serotonin Levels Correlate with the Abundance of Certain Bacterial Taxa {#s0105}
---------------------------------------------------------------------------------------------------

Gut microbes, in particular spore-forming clostridia, have been shown to regulate 5-HT metabolism in the GI tract ([@bb0375]). To this end, we investigated whether observed changes in the intestinal transit and 5-HT levels in the gut were associated with alterations in the abundance of any particular bacterial taxa. We found that both 5-HT tissue levels and intestinal transit rate were strongly correlated with the relative abundance of *Firmicutes* bacteria; this correlation was mainly driven by the *Blautia* genus of the *Clostridiales* order ([Fig. 2](#f0010){ref-type="fig"}g). There were also strong correlations between the abundance of *Blautia* and *Tph1, Sert* and *Ido1* gene expression levels (Table S3). Similar, but weaker associations were observed with the *Lachnospiraceae Incertae Sedis* genus of the same order. These findings confirm the importance of clostridia bacteria in the maintenance of normal peristalsis and 5-HT synthesis in the gut.

3.5. BTBR Mice Display Deficits in the Development of the Enteric Nervous System {#s0110}
--------------------------------------------------------------------------------

Healthy motility of the GI tract relies heavily on the enteric nervous system (ENS). We thus aimed to investigate whether delayed colonic transit in BTBR mice could have also been attributed to abnormal development of motor circuits in the ENS. For this, we stained the myenteric plexus (MP) in distal colon against choline acetyltransferase (ChAT), which is expressed in a vast majority of myenteric neurons including excitatory motor neurons, and against neuronal NO synthase (nNOS), which is expressed in inhibitory motor neurons of MP ([@bb0100]). ChAT staining showed the fine structure of MP with ganglia and interganglionic fibers ([Fig. 3](#f0015){ref-type="fig"}a). The morphometric analysis revealed a substantial reduction in the spatial density of MP in BTBR mice: the area occupied by MP was decreased, while the interganglionic space was increased ([Fig. 3](#f0015){ref-type="fig"}b). Furthermore, we found a 50% reduction in the numbers of inhibitory motor neurons (nNOS) and total myenteric neurons (pan-neuronal HuC/HuD marker) ([Fig. 3](#f0015){ref-type="fig"}c--d). These data suggest an abnormal development of both excitatory and inhibitory motor neurons in BTBR mice. These are interesting data in the context of recent findings indicating that the gut microbiota is essential for the development of the ENS ([@bb0050]; [@bb0285]).Fig. 3BTBR mice display deficits in the development of the enteric nervous system (a) Anti-ChAT staining (green) in whole mount preparations of distal colon revealed the fine structure of myenteric plexus (MP), with ganglia and interconnecting fibers. Cellular nuclei were stained with DAPI (blue). (b) The spatial density of MP was decreased in BTBR mice. (c) Myenteric ganglia were co-stained against pan-neuronal marker HuC/HuD (green) and nNOS (red). (d) BTBR mice showed a reduction in total and nNOS-positive neuronal numbers. Scale bar represents 100 μm \**p* \< 0.05 for BTBR vs. C57BL/6 group. *Statistical analysis*: data are presented as median with IQR and min/max values as error bars; *n* = 5 in either group. *U*~(9)~ = 0.000, *p* = 0.004 for MP area; *U*~(9)~ = 30.000, *p* = 0.004 for interganglionic space; *U*~(9)~ = 6.000, *p* = 0.126 for MP contact ratio; *U*~(9)~ = 5.000, *p* = 0.082 for MP thickness; *U*~(8)~ = 0.000, *p* = 0.008 for HuC/HuD neurons; *U*~(8)~ = 0.000, *p* = 0.008 for nNOS neurons, Mann-Whitney test.Fig. 3

3.6. BTBR Mice Have Differential Changes in Epithelial Permeability in Small and Large Intestine {#s0115}
------------------------------------------------------------------------------------------------

Along with altered bowel habits, ASD has been associated with impaired intestinal barrier function ([@bb0080]; [@bb0065]; [@bb0095]). To characterize epithelial permeability in the BTBR intestine, we measured the efficacy of macromolecular diffusion across the epithelium *ex vivo* (4 kDa FITC flux). In the distal ileum, we observed a dramatic increase in epithelial permeability in BTBR mice ([Fig. 4](#f0020){ref-type="fig"}a). FITC flux was increased approximately two-fold at the 60 min time point and remained consistently elevated over the next two hours of the assay (*p* = 0.019 for the effect of genotype, *F*~(1;14)~ = 7.090). Macromolecular permeability of intestinal epithelium is largely dependent on the proper function of tight junctions (TJs) ([@bb0380]). Despite an increase in FITC flux, we failed to find substantial alterations in the gene expression levels of either TJ proteins (*Cldn1*, *Ocln* and *Tjp1*) or proteins regulating the assembly and energy supply to TJs (*Ckb*, *Ckm*, *Mylk*) ([@bb0120]; [@bb0320]) ([Fig. 4](#f0020){ref-type="fig"}b).Fig. 4Differential changes to epithelial permeability and tight junction-associated gene expression in small and large intestine of BTBR mice (a) In distal ileum, BTBR mice showed a marked increase in FITC transepithelial permeability, with no substantial changes to either tight junction-associated genes (b) or mucin2 gene expression (e). (c) In the colon of BTBR mice, FITC permeability was increased in the end, but decreased in the beginning of the incubation period. The biphasic response of FITC flux was coupled with an up-regulation of tight junction protein genes, but a down-regulation of creatine kinase and mucin2 genes (d--e). (f) TEER was not changed, while *I*~*sc*~ was substantially decreased in the BTBR intestine. \**p* \< 0.05 for BTBR vs. C57BL/6 group. *Statistical analysis*: data are presented as mean + SEM, *n* = 10 in either group. FITC permeability in distal ileum: *F*~(6;84)~ = 63.339, *p* \< 0.0005 for the effect of Time, *F*~(1;14)~ = 7.090, *p* = 0.019 for the effect of Genotype, *F*~(6;84)~ = 7.177, *p* = 0.015 for the Time × Genotype interaction. FITC permeability in the colon: *F*~(6;102)~ = 383.858, *p* \< 0.0005 for the effect of Time, *F*~(1;17)~ = 0.061, *p* = 0.808 for the effect of Genotype, *F*~(6;102)~ = 9.198, *p* = 0.002 for the Time × Genotype interaction. Datasets were analyzed with mixed-design ANOVA with Genotype as an independent factor and Time as a repeated measure. Mean values in each time point were further compared between groups with unpaired *t*-test. *t*~(14)~ = 1.582, *p* = 0.136 for TEER; *t*~(14)~ = 6.862, *p* \< 0.0005 for *Isc*; *t*~(18)~ = 0.624, *p* = 0.541 for *Cldn1*, *t*~(18)~ = − 1.429, *p* = 0.170 for *Ocln*, *t*~(18)~ = − 2.768, *p* = 0.013 for *Tjp1*, *t*~(15)~ = − 3.292, *p* = 0.005 for *Ckb*, *t*~(16)~ = − 3.731, *p* = 0.002 for *Ckm*, *t*~(15)~ = 0.217, *p* = 0.831 for *Mylk*, *t*~(17)~ = 1.278, *p* = 0.218 for *Muc2* gene expression in distal ileum, unpaired *t*-test. *t*~(18)~ = 1.101, *p* = 0.285 for TEER; *t*~(18)~ = 4.407, *p* = 0.001 for *Isc*; *t*~(18)~ = − 6.319, *p* \< 0.0005 for *Cldn1*, *t*~(18)~ = − 2.273, *p* = 0.035 for *Ocln*, *t*~(18)~ = 0.104, *p* = 0.918 for *Tjp1*, *t*~(17)~ = 4.791, *p* \< 0.0005 for *Ckb*, *t*~(17)~ = 3.255, *p* = 0.005 for *Ckm*, *t*~(17)~ = 5.751, *p* \< 0.0005 for *Mylk*, *t*~(17)~ = 6.261, *p* \< 0.0005 for *Muc2* gene expression in the colon, unpaired *t*-test.Fig. 4

Colonic tissue showed a very distinct profile of macromolecular permeability in BTBR mice ([Fig. 4](#f0020){ref-type="fig"}c). During the first 90 min of the assay, FITC flux was slightly decreased (*p* = 0.002 for the time × genotype interaction, *F*~(6;102)~ = 9.198; *p* = 0.003 for 60 min and *p* = 0.057 for 90 min). However, during the following 90 min, FITC flux in BTBR samples substantially accelerated, overtaking the control group and reaching significantly higher levels by the end of the assay (*p* = 0.029 for 180 min). Gene expression analysis shed some light on the biphasic response of FITC permeability ([Fig. 4](#f0020){ref-type="fig"}d). On one hand, a marked increase in *Cldn1* gene expression can explain a functionally "tighter" epithelium in the BTBR colon at baseline. On the other hand, a 50% down-regulation of creatine kinase *Ckb* and *Ckm* genes suggests a reduced efficacy of phosphocreatine metabolic shuttle turnover, which is critically important for the maintenance of energy supply to TJs ([@bb0120]). This would favor a rapid increase in macromolecular permeability in BTBR samples in *ex vivo* conditions, when tissue specimens are exposed to limited oxygen and substrate supply. Furthermore, these findings suggest that the BTBR colon might be less resilient to any metabolic stress *in vivo*, such as intestinal inflammation or hypoxia.

The epithelial mucus layer also helps to maintain the physical barrier between the gut and the lumen ([@bb0150]). Interestingly, the expression of *Muc2*, a gene encoding mucin 2, which is the major constituent of mucus layer, was down-regulated in the large intestine of BTBR mice, but not in distal small intestine ([Fig. 4](#f0020){ref-type="fig"}e). Despite marked alterations in FITC permeability, only marginal changes in ion conductance (TEER) were observed in either ileum or colon samples of BTBR mice ([Fig. 4](#f0020){ref-type="fig"}f, left panel). Although at first glance counterintuitive, these findings are supported by the current model of junctional gate ([@bb0380]), whereby ions and molecules use different pathways to diffuse through the tight junction. TEER and macromolecular permeability of the intestinal epithelium can thus be differentially regulated and even functionally decoupled ([@bb0020]).

3.7. Reduced Activity of Electrolyte Transport in the BTBR Intestine {#s0120}
--------------------------------------------------------------------

We analyzed *I*~*sc*~ values in BTBR and C57BL/6 intestine as a measure of electrolyte transport across the epithelium. In both small and large intestine, *I*~*sc*~ was substantially decreased in BTBR mice ([Fig. 4](#f0020){ref-type="fig"}f, right panel). This suggests either a reduction in Na^+^ absorption from the gut lumen and/or a decrease in Cl^−^ secretion into the lumen. Interestingly, we observed a down-regulation of *Slc5a1* gene in the BTBR ileum (Fig. S2a). *Slc5a1* encodes apical Na^+^/glucose co-transporter, which is known to enhance intestinal *I*~*sc*~ in the presence of luminal glucose ([@bb0030]; [@bb0355]). Activation of Cl^−^ secretion in the colon is associated with water retention in the lumen and, when reaching pathological levels, diarrhea ([@bb0345]). In this regard, a reduction in Cl^−^ secretion in the BTBR colon would be consistent with decreased fecal water contents and delayed colonic transit ([Fig. 2](#f0010){ref-type="fig"}b--d).

3.8. Intestinal Permeability Correlates With the Abundance of Certain Bacterial Taxa {#s0125}
------------------------------------------------------------------------------------

Gut bacteria and their metabolites can modulate intestinal barrier function ([@bb0180]); therefore, we examined the associations between microbiota composition and intestinal macromolecular permeability (Table S3). Interestingly, here we observed a different correlation profile in comparison with the one found for intestinal transit and 5-HT metabolism. From the *Firmicutes* phylum, correlations with *Blautia* genus were largely lost. Instead, a strong negative association between the abundance of *Ruminococcaceae Incertae Sedis* bacteria and FITC permeability was observed. In *Bacteroidetes*, a strong positive correlation between FITC flux and *S24--7 uncultured bacterium* abundance was present. Many of these differences can be driven by a unique metabolic profile of each bacterial genus, including the production of different biologically active compounds, such as SCFAs or indoles ([@bb0185]; [@bb0310]).

3.9. BTBR Mice Display Reduced Plasma Bile Acid Levels and Deficient Bile Acid Signaling in the Ileum {#s0130}
-----------------------------------------------------------------------------------------------------

Epithelial permeability data ([Fig. 4](#f0020){ref-type="fig"}) clearly demonstrated functional differences between the colon and the ileum in BTBR mice. One of the unique features of the terminal small intestine is the active uptake of the bile from the intestinal lumen ([@bb0060]). Primarily, bile acids (BAs) assist in the digestion of dietary lipids and regulate lipid metabolism. In the small intestine, they are also very important for the maintenance of epithelial barrier function ([@bb0105]; [@bb0145]). Hence, we measured BAs in plasma and fecal matter of BTBR and C57BL/6 mice ([Fig. 5](#f0025){ref-type="fig"} and Table S4). In plasma, the levels of tauro-conjugated and unconjugated BAs were overall decreased in BTBR mice ([Fig. 5](#f0025){ref-type="fig"}a). About 95% of the bile released into the gut is actively re-absorbed in distal ileum to ensure the complete enterohepatic circulation. Thus, a decrease in plasma BAs in BTBR mice could be attributed to a deficit in either BA synthesis or BA re-uptake. We did not find any changes in the gene expression of intestinal BA transporters (*Asbt*, *Fabp6, Ostα*) or liver BA transporters (*Ntcp, Bsep*) across the groups ([Fig. 5](#f0025){ref-type="fig"}b--c). These findings rule out the BA malabsorption in BTBR mice. Instead, there was a trend towards a reduction in the expression of *Cyp7a1* gene, which encodes a rate-limiting enzyme in the classical pathway of BA synthesis in the liver ([Fig. 5](#f0025){ref-type="fig"}c). Interestingly, the expression of *Cyp7b1* gene, which encodes a rate-limiting enzyme in the alternative pathway of BA synthesis, was up-regulated in BTBR mice. When absorbed in distal ileum, BAs activate the farnesoid X receptor (FXR) in enterocytes. The expression levels of *Fxr* gene, as well as its partners *Rxrα* and *Hnf4α*, were unchanged in the BTBR ileum ([Fig. 5](#f0025){ref-type="fig"}b). However, the downstream targets of this receptor, in particular *Fgf15* and *Nos2*, were substantially down-regulated. Intestinal Fgf15 is a potent inhibitor of *Cyp7a1* expression and BA synthesis ([@bb0205]). Hence, it is surprising that the suppression of the intestinal Fxr/Fgf15 signaling pathway failed to up-regulate *Cyp7a1* gene expression in the liver of BTBR mice. On the other hand, *Cyp7a1* expression can be activated by the nuclear receptors Pgc-1α and Ppar-γ ([@bb0085]; [@bb0330]). Similar to *Cyp7a1*, the expression levels of both *Pgc-1α* and *Pparγ* genes were decreased in the BTBR liver ([Fig. 5](#f0025){ref-type="fig"}c), suggesting that multiple nuclear receptors are implicated in the decreased BA synthesis observed in BTBR mice.Fig. 5Altered bile acid signatures and deficient bacterial metabolism of bile moieties in BTBR mice (a) In plasma, a reduction in unconjugated and tauro-conjugated BA levels was seen in BTBR mice. (b--c) The gene expression levels of BA transporters were not altered in the distal ileum or liver of BTBR mice. In contrast, *Cyp7a1* and *Pparg* genes in the liver, as well as *Fgf15* and *Nos2* genes in the ileum were down-regulated in BTBR mice. (d) In the fecal matter of BTBR mice, a dramatic increase in all tauro-conjugated BAs and a trend towards a reduction in unconjugated secondary BAs were observed. \**p* \< 0.05 for BTBR vs. C57BL/6 group. *Statistical analysis*: data are presented as median with IQR and min/max values as error bars on (a) and (d), and as mean + SEM on (b) and (c). *U*~(11)~ = 11.000, *p* = 0.181 for total BAs, *U*~(11)~ = 7.000, *p* = 0.051 for CA, *U*~(11)~ = 2.000, *p* = 0.005 for CDCA, *U*~(11)~ = 19.000, *p* = 0.836 for β-MCA, *U*~(10)~ = 1.500, *p* = 0.005 for DCA, *U*~(11)~ = 25.000, *p* = 0.628 for LCA, *U*~(11)~ = 0.000, *p* = 0.001 for UDCA, *U*~(10)~ = 10.000, *p* = 0.268 for total TBAs, *U*~(10)~ = 13.000, *p* = 0.530 for TCA, *U*~(10)~ = 5.000, *p* = 0.048 for TCDCA, *U*~(10)~ = 8.000, *p* = 0.149 for Tβ-MCA, *U*~(10)~ = 10.000, *p* = 0.268 for TDCA, *U*~(10)~ = 27.000, *p* = 0.149 for TLCA, *U*~(10)~ = 2.000, *p* = 0.010 for TUDCA levels in plasma, *n* = 7 in C57BL/6 and *n* = 6 in BTBR group, Mann-Whitney test. *U*~(11)~ = 16.000, *p* = 0.534 for total BAs, *U*~(11)~ = 25.000, *p* = 0.628 for CA, *U*~(11)~ = 17.000, *p* = 0.628 for CDCA, *U*~(11)~ = 34.000, *p* = 0.073 for β-MCA, *U*~(11)~ = 10.000, *p* = 0.138 for DCA, *U*~(11)~ = 6.000, *p* = 0.035 for LCA, *U*~(11)~ = 10.000, *p* = 0.138 for UDCA, *U*~(11)~ = 39.000, *p* = 0.008 for total TBAs, *U*~(11)~ = 35.000, *p* = 0.051 for TCA, *U*~(11)~ = 37.000, *p* = 0.022 for TCDCA, *U*~(11)~ = 38.000, *p* = 0.014 for Tβ-MCA, *U*~(11)~ = 40.000, *p* = 0.005 for TDCA, *U*~(11)~ = 39.000, *p* = 0.008 for TLCA, *U*~(11)~ = 42.000, *p* = 0.001 for TUDCA levels in the fecal matter, n = 7 in C57BL/6 and n = 6 in BTBR group, Mann-Whitney test. *t*~(18)~ = − 0.081, *p* = 0.936 for *Fxr*, *t*~(18)~ = − 0.488, *p* = 0.632 for *Rxra*, *t*~(18)~ = − 0.726, *p* = 0.477 for *Hnf4a*, *t*~(17)~ = 2.776, *p* = 0.013 for *Fgf15*, *t*~(18)~ = 2.807, *p* = 0.012 for *Nos2*, *t*~(18)~ = − 0.102, *p* = 0.920 for *Asbt*, *t*~(18)~ = − 0.373, *p* = 0.714 for *Fabp6*, *t*~(18)~ = − 0.118, *p* = 0.907 for *Osta* gene expression in distal ileum, n = 10 in either group, unpaired *t*-test. *t*~(11)~ = 1.887, *p* = 0.086 for *Cyp7a1*, *t*~(12)~ = − 3.157, *p* = 0.008 for *Cyp7b1*, *t*~(12)~ = − 0.274, *p* = 0.788 for *Fxr*, *t*~(12)~ = − 0.905, *p* = 0.383 for *Rxra*, *t*~(12)~ = − 0.525, *p* = 0.609 for *Hnf4a*, *t*~(11)~ = 3.189, *p* = 0.009 for *Pparg*, *t*~(12)~ = 2.190, *p* = 0.061 for *Pgc-1a*, *t*~(12)~ = 0.167, *p* = 0.870 for *Ntcp*, *t*~(12)~ = − 0.274, *p* = 0.788 for *Bsep* gene expression in the liver, *n* = 8 in C57BL/6 and n = 6 in BTBR group, unpaired *t*-test.Fig. 5

3.10. BTBR Mice Display a Deficit in the Microbial Conversion of Bile {#s0135}
---------------------------------------------------------------------

Bile that is not re-absorbed in terminal small intestine undergoes further transformation by the intestinal microbiota ([@bb0155]). First, gut bacteria de-conjugate BAs from taurine and glycine. Second, unconjugated primary BAs (cholic acid (CA), chenodeoxycholic acid (CDCA) and muricholic acid (MCA) in mice) are processed into secondary BAs, such as deoxycholic acid (DCA), lithocholic acid (LCA) and ursodeoxycholic acid (UDCA). In the fecal matter of BTBR mice, we observed a remarkable increase in all conjugated BAs, for both primary and secondary conjugates ([Fig. 5](#f0025){ref-type="fig"}d, right panel). Further, we saw a significant reduction in secondary bile acid LCA, with a similar trend in DCA and UDCA ([Fig. 5](#f0025){ref-type="fig"}d, left panel). Moreover, the ratio between secondary and primary unconjugated BAs was significantly decreased in BTBR mice (Fig. S3). These data indicate that the BTBR microbiota has a reduced capacity to metabolize host bile.

3.11. Changes in the Gut Microbiota are Associated with a Robust Autistic-like Behavioral Phenotype {#s0140}
---------------------------------------------------------------------------------------------------

We characterized the ASD-relevant behavioral phenotype in BTBR mice ([Fig. 6](#f0030){ref-type="fig"}). In agreement with previous reports ([@bb0255]), BTBR mice demonstrated impaired social interactions (a--c) and enhanced engagement in repetitive behaviors (e--f), as well as increased anxiety levels (h--k). Here we found decreased levels of social behavior-related hormone oxytocin in BTBR plasma (d). Further, BTBR mice displayed higher baseline levels of the stress hormone corticosterone, as well as elevated corticosterone values at the peak of the acute stress response and during the subsequent recovery phase ([Fig. 6](#f0030){ref-type="fig"}l, p \< 0.05 for the effect of genotype, F~(1;16)~ = 8.193). Despite this hyper-corticosterone phenotype, BTBR mice had smaller adrenal glands, and increased expression of the glucocorticoid receptor gene in the hippocampus ([Fig. 6](#f0030){ref-type="fig"}m--n). Interestingly, the expression of *Cyp11a1*, a gene encoding the first rate-limiting enzyme in the production of corticosterone, was substantially up-regulated in the distal ileum of BTBR mice (Fig. S2b). Taken on its own, this transcriptional shift does not necessarily implicate an increase in intestinal hormonal levels. However, if local production of corticosterone was elevated in the BTBR ileum, this could explain increased levels of circulating hormone ([Fig. 6](#f0030){ref-type="fig"}l) ([@bb0265]). This could also affect the GI physiology in BTBR mice including an up-regulation of *Tdo2* gene in distal ileum ([Fig. 2](#f0010){ref-type="fig"}f, see also [Discussion](#s0145){ref-type="sec"}).Fig. 6Autistic-like behavioral phenotype in BTBR mice (a--d) BTBR mice displayed impaired social interactions, as well as decreased plasma levels of oxytocin. (e--f) BTBR mice were largely engaged in compulsive behaviors. They showed impaired working memory performance (g), enhanced locomotor activity and anxiety-like behavior (h, i and k). (j) No evidence of depressive-like behavior was observed. (l) BTBR mice displayed elevated plasma corticosterone levels at baseline and when being exposed to an acute stressor (forced swim test). (m--n) BTBR mice had smaller adrenal glands and increased expression of glucocorticoid receptor gene in the hippocampus. \**p* \< 0.05 for BTBR vs. C57BL/6 group. *Statistical analysis*: data are presented as median with IQR and min/max values as error bars on (e) and (k), and as mean + SEM on the rest, n = 10 in either group. *t*~(18)~ = 8.153, *p* \< 0.0005 for Mouse vs Object and *t*~(17)~ = 3.707, *p* = 0.002 for Novel vs Familiar Mouse preference; *t*~(18)~ = 5.678, *p* \< 0.0005 for the RI interaction; *t*~(13)~ = 3.485, *p* = 0.004 and *t*~(13)~ = 2.029, *p* = 0.063 for the cued food preference at 0 h and 24 h time points, respectively; *t*~(17)~ = 3.623, *p* = 0.002 for oxytocin levels; *t*~(18)~ = − 6.303, *p* \< 0.0005 for self-grooming time; *t*~(18)~ = 3.040, *p* = 0.011 for the NOR discrimination index; *t*~(18)~ = 0.059, *p* = 0.953 for the time in the center, *t*~(18)~ = − 2.090, *p* = 0.051 for the latency to enter the center and *t*~(18)~ = − 7.099, *p* \< 0.0005 for the distance travelled in the OF test; *t*~(17)~ = 2.947, *p* = 0.009 for open arm entries in the EPM test; *t*~(18)~ = 2.785, *p* = 0.012 for the immobility time in the FST test; *t*~(18)~ = 3.229, *p* = 0.005 for the adrenal glands weight; *t*~(17)~ = − 5.480, *p* \< 0.0005 for the *Gr* and *t*~(17)~ = − 1.845, *p* = 0.094 for the *Mr.* gene expression, unpaired *t*-test. *U*~(18)~ = 83.000, *p* = 0.011 for \# of buried marbles; *U*~(18)~ = 99.000, *p* \< 0.0005, *U*~(18)~ = 98.000, *p* \< 0.0005 and *U*~(18)~ = 83.000, *p* = 0.001 for \# of fecal pellets in the OF, NOR and EPM tests, respectively, Mann-Whitney test. Plasma Corticosterone: *F*~(5;80)~ = 209.091, *p* \< 0.0005 for the effect of Time, *F*~(1;16)~ = 8.193, *p* = 0.011 for the effect of Genotype, *F*~(5;80)~ = 1.534, *p* = 0.221 for the Time × Genotype interaction. Datasets were analyzed with mixed-design ANOVA with Genotype as an independent factor and Time as a repeated measure. Mean values in each time point were further compared between groups with unpaired *t*-test.Fig. 6

Correlation analysis between the relative abundance of bacterial taxa and behavioral scores showed an impressively strong association between the gut microbiota and the behavioral phenotype ([Fig. 7](#f0035){ref-type="fig"}). *Rikenella*, *Parabacteroides*, *Odoribacter*, *Desulfovibrio*, *Blautia* and *Bifidobacterium* species (all reduced in abundance in BTBR mice) were positively correlated with the social behavior scores and negatively correlated with the repetitive behaviors and anxiety phenotype. For the *S24--7 family*, *Bilophila* and *Bacteroides* species (all increased in abundance in BTBR mice), a negative association with sociability levels and a positive association with compulsive and anxiety-like behaviors was observed ([Fig. 7](#f0035){ref-type="fig"}). Given the tight interactions between the gut microbiota and GI functions (Table S3), it is perhaps not surprising that behavioral scores were also associated with changes in the intestinal serotonin levels and other GI parameters assessed (Fig. S4).Fig. 7A strong association between behavioral scores and gut microbiota composition A correlation matrix showing positive (red) and negative (blue) associations between behavioral scores and the relative abundance of bacterial genera in BTBR and C57BL/6 mice. Significant correlations are marked with asterisks. \**p* \< 0.05, \*\**p* \< 0.01 and \*\*\**p* \< 0.001, Spearman\'s rank correlation analysis, Benjamini-Hochberg adjusted *p* values with a FDR of 0.05.Fig. 7

4. Discussion {#s0145}
=============

The BTBR mouse strain is a very popular and useful animal model of ASD, with a robust autistic-like behavioral phenotype ([@bb0255]). Here we show that social behavior deficits in BTBR mice are associated with marked GI distress, evidenced by changes in intestinal permeability, transit and the ENS morphology, as well as with altered microbiota composition. BTBR mice displayed profound changes in the cecal microbiota, with 18 out of 44 identified bacterial genera being differentially altered (Table S2). These included bacterial taxa that have previously been shown to be important for host health, and some of them associated with ASD: *Akkermansia*, *Bifidobacterium*, *Blautia*, *Desulfovibrio*, *Bilofila*, etc. ([@bb0170]; [@bb0365]). A significant reduction in the relative abundance of *Blautia* and *Bifidobacterium* genera is of particular interest with respect to GI physiology in BTBR mice. Indeed, *Blautia* bacteria belong to the *Clostridiales* order, representatives of which have been shown to modulate 5-HT metabolism in the host by increasing the expression of *Tph1* in the gut, activating 5-HT synthesis and accelerating GI motility ([@bb0375]). Furthermore, *Blautia* and *Bifidobacterium* species are involved in the transformation of host bile. *Bifidobacterium*, along with *Lactobacillus* and a few other taxa, express bile salt hydrolase enzymes, which carry out de-conjugation of BAs from taurine or glycine ([@bb0025]); this is the first step in bacterial conversion of bile ([@bb0155]). Of note, lactobacilli also tended to be decreased in the BTBR gut (Table S2). Unconjugated primary BAs are further transformed into secondary BAs as a result of 7α-dehydroxylation activity, which is present in some members of *Clostridium* cluster XIVa including *Blautia* species ([@bb0300]). Therefore, a substantial loss in *Blautia* and *Bifidobacterium* species in the BTBR microbiota strongly suggests that the efficacy of bacteria-mediated bile transformation, as well as the effect of bacteria on 5-HT production are impaired in the BTBR intestine.

The follow-up analysis of bile moieties and tryptophan metabolites in the BTBR gut confirmed the sequencing-based functional predictions. First, we observed a dramatic increase in all conjugated BAs, as well as a reduction in secondary BA pool in BTBR fecal matter ([Fig. 5](#f0025){ref-type="fig"}d and Fig. S3). These data indicate that both bile salt hydrolase and 7α-dehydroxylation activities are compromised in the BTBR microbiota. Secondly, we found a marked reduction in 5-HT bioavailability in BTBR small and large intestine due to a decrease in 5-HT synthesis and an increase in 5-HT breakdown ([Fig. 2](#f0010){ref-type="fig"}e--f). Strikingly, intestinal 5-HT levels and *Tph1* gene expression were strongly and positively correlated with the relative abundance of *Blautia* genus ([Fig. 2](#f0010){ref-type="fig"}g, Table S3). Hence, the observed reduction in the abundance of *Blautia* species could underlie the deficit in 5-HT production in the BTBR gut.

Changes in either tryptophan metabolism or the microbial conversion of bile can have a tremendous impact on GI physiology. Secondary BAs, produced by gut bacteria, have a unique signaling profile in the GI tract as compared with primary bile moieties. For example, secondary BAs were shown to activate colonic motility by stimulating the release of intestinal 5-HT and CGRP ([@bb0005]). Therefore, a reduction in secondary BA levels could contribute to the delayed colonic transit in BTBR mice ([Fig. 2](#f0010){ref-type="fig"}b--d). Further, tauro-conjugated β-MCA has recently been shown to be a potent natural antagonist of Fxr receptor in mice and to inhibit its downstream signaling ([@bb0315]). Hence, an increase in Tβ-MCA intestinal levels can explain the observed down-regulation of *Fgf15* gene expression in the BTBR ileum ([Fig. 5](#f0025){ref-type="fig"}b and d). In addition to the deficits in bacteria-mediated bile conversion, BTBR mice displayed a reduction in plasma BA levels, most likely due to a decrease in BA synthesis along the classical Cyp7a1-mediated pathway ([Fig. 5](#f0025){ref-type="fig"}a and c). This can have deleterious consequences for the intestine as well. BAs are toxic for many bacterial species; they also induce the expression of anti-microbial defense genes in the host (including iNOS, RegIIIγ) ([@bb0145]; [@bb0160]). In fact, a reduction in the luminal BA levels has been associated with small intestine bacterial overgrowth, activation of inflammation, and subsequent damage to the epithelium ([@bb0145]; [@bb0225]). A down-regulation of *iNos* (*Nos2*) gene expression in the ileum of BTBR mice ([Fig. 5](#f0025){ref-type="fig"}b) suggests that anti-microbial defense can be compromised in the BTBR intestine, which in turn could contribute to the impairment of small intestine barrier function ([Fig. 4](#f0020){ref-type="fig"}a).

Similar to bile moieties, tryptophan metabolites are involved in the regulation of essential GI functions. 5-HT activates intestinal peristalsis and electrolyte secretion, supports the development of the ENS and amplifies inflammatory responses in the gut ([@bb0110]; [@bb0135]; [@bb0220]; [@bb0240]). Hence, a decrease in 5-HT bioavailability can explain delayed intestinal transit and reduced activity of electrolyte transport seen in BTBR mice ([Figs. 2](#f0010){ref-type="fig"}a--d, [4](#f0020){ref-type="fig"}f). Interestingly, metabolism of tryptophan along the kynurenine route also seems to be affected in BTBR mice. The expression levels of *Ido1* and *Tdo2* genes, which encode alternative rate-limiting enzymes in this pathway, were markedly altered in the BTBR intestine ([Fig. 2](#f0010){ref-type="fig"}e--f). *Tdo2* gene expression is responsive to stress and is under a tight control of glucocorticoids ([@bb0125]). Strikingly, we found an increased expression of *Cyp11a1* gene in the BTBR ileum (Fig. S2b), which could have resulted in elevated production of corticosterone and an up-regulation of *Tdo2* locally in the BTBR ileum ([Fig. 2](#f0010){ref-type="fig"}f). The observed changes in intestinal *Ido1* and *Tdo2* gene expression are very unlikely to have a direct effect on the brain in BTBR mice. Indeed, \> 90% of tryptophan is catabolized down to kynurenine in the liver, with liver Tdo2 activity determining the systemic levels of kynurenine, and the availability of tryptophan for the brain ([@bb0185]). To this end, neither the expression of liver *Tdo2* nor the plasma levels of tryptophan was altered in BTBR mice (Fig. S5a--b). However, this will certainly affect the intestinal levels of kynurenine and its metabolites (kynurenic and quinolinic acids), and local effects on the BTBR gut physiology are thus very plausible. For instance, kynurenic acid is known to slow the intestinal transit by inhibiting the enteric NMDA receptors, as well as to dampen the inflammatory response in the gut ([@bb0090]; [@bb0175]; [@bb0190]). Moreover, both 5-HT and kynurenine metabolites can alter the activity of intestinal vagal afferents, and hence, might directly affect vagal signaling to the brain ([@bb0335]). Of note, recent evidence suggests altered 5-HT and kynurenine metabolism in ASD ([@bb0035]; [@bb0215]; [@bb0270]).

Altered tryptophan metabolism and inadequate bacterial conversion of bile are thus very likely to contribute to both intestinal dysmotility and impaired gut barrier function in BTBR mice. Maintenance of epithelial integrity is critically important not only for gut health, but also for brain health. The phenomenon of "leaky" gut has recently been extended beyond GI disorders, such as irritable bowel syndrome, to psychiatric diseases, such as depression ([@bb0180]). Dysfunctional intestinal barrier in BTBR mice can permit the microbiota to induce low-grade inflammation in the gut. This shift towards a pro-inflammatory state, particularly in combination with an anxious phenotype ([Fig. 6](#f0030){ref-type="fig"}h--l), can in turn trigger the activation of neuroinflammatory responses in the brain ([@bb0295]; [@bb0370]) and exaggerate autistic-like behavioral deficits in BTBR mice. Indeed, the BTBR mouse has been shown to display a pro-inflammatory phenotype that is thought to contribute to the development of ASD-like behavior ([@bb0045]; [@bb0130]; [@bb0290]). Interestingly, we found that deficits in social behavior in BTBR mice were accompanied by a decrease in plasma oxytocin levels ([Fig. 6](#f0030){ref-type="fig"}d). Oxytocin is one of the key hormones involved in supporting the salience of social interactions, and is known to be modulated by intestinal microbiota ([@bb0040]; [@bb0360]).

In summary, here we show that the BTBR mouse displays marked GI dysfunction ([Fig. 8](#f0040){ref-type="fig"}). Similar to human ASD, BTBR mice have "leaky" intestinal epithelium and delayed intestinal transit. We further identify deficient bacterial transformation of bile moieties and impaired tryptophan metabolism in the BTBR intestine as potential mechanisms underlying GI symptoms in these animals. Taking advantage of microbiota sequencing and physiological data, we associate these functional changes with a reduction in the relative abundance of *Bifidobacterium* and *Blautia* bacteria in the BTBR microbiota. These data offer specific targets in the gut microbiota for improving gastrointestinal and, perhaps, behavioral symptomatology in the BTBR mouse model of autism, and support the concept of microbiota-based interventions in ASD.Fig. 8Putative mechanisms linking changes in the gut microbiota with GI malfunction in the BTBR mouse model of human ASD. In BTBR mice, autistic-like behavioral phenotype is associated with altered microbiota and marked GI distress: increased epithelial permeability (1) and delayed intestinal motility (2). (1) Reduced abundance of bile-metabolizing *Bifidobacterium* species increases the fraction of tauro-conjugated BAs (e.g. tauromuricholic acid (TβMCA)) in the GI tract. TβMCA inhibits Fxr signaling and thus supresses anti-microbial defense of the host (iNOS, RegIIIγ). We hypothesise that loss of Fxr signaling in BTBR mice causes small intestinal bacterial overgrowth and, as a result, an increase in epithelial permeability. This effect is further exaggerated by deficient synthesis of BAs, which normally prevent bacterial overgrowth. (2) Healthy intestinal transit relies on many factors, including the ENS, secondary BAs and 5-HT (all deficient in BTBR mice). Secondary BA levels are reduced; 5-HT bioavailability is decreased due to a lower production (down-regulation of *Tph1*) and a higher breakdown (up-regulation of *Sert*) rates. Lower abundance of clostridia bacteria, including *Blautia* species, potentially contributes to these changes. Further, the BTBR myeneric plexus shows reduced numbers of excitatory and inhibitory neurons. All this can cause delayed intestinal motility in BTBR mice.Fig. 8
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